Pharmacodynamic and pharmacokinetic effects of the intravenous CB1 receptor agonist Org 26828 in healthy male volunteers

Abstract

An ideal drug for outpatient treatments under conscious sedation would have both sedative and analgesic properties. CB1/CB2 agonists are expected to have sedative, amnestic, analgesic and anti-emetic properties. The main objective of this first study in humans was to assess the sedative properties of intravenous Org 26828. In addition, pharmacokinetics, amnestic properties, postural stability, and behavioural and cardiovascular effects were studied. Midazolam intravenous 0.1 mg/kg and placebo were used as controls. The pharmacokinetic parameters (Cmax and AUC0-inf) of the main metabolite Org 26761 were proportional to dose. No effects were observed after doses up to 0.3 μg/kg of Org 26828. Dose-related effects were observed at higher doses. Although subjects reported subjective sedation after administration of Org 26828 at 3 and 6 μg/kg, the observed sedation was considerably less than after midazolam. Doses higher than the maximum tolerated dose of 1 μg/kg of Org 26828 caused unpleasant central nervous system effects (anxiety, paranoia, hallucinations). Therefore, Org 26828 is not suitable for providing sedation for outpatient surgical procedures.

Keywords

cannabinoid CB1 receptor agonist Org 26828 human intravenous sedation healthy volunteers pharmacodynamics pharmacokinetics

Get full access to this article

View all access options for this article.

References

Ameri A. ( 1999) The effects of cannabinoids on the brain. Prog Neurobiol 58: 315-348.

Bond A. , Lader M. ( 1974) The use of analogue scales in rating subjective feelings . Brit J Med Psychol 47: 211-218.

Bowdle TA , Radant AD , Cowley DS , Kharasch ED , Strassman RJ , Roy-Byrne PP ( 1998) Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology 88: 82-88.

de Roode A. , van Gerven JM , Schoemaker RC , et al. (2000) A comparison of the effects of propofol and midazolam on memory during two levels of sedation by using target-controlled infusion. Anesth Analg 91: 1056-1061.

de Visser S. , van der Post J. , de Waal P. , Cornet F. , Cohen A. , van Gerven J. ( 2003) Biomarkers for the effect of benzodiazepines in healthy volunteers. Brit J Clin Pharmacol 55: 39-50.

D’Souza DC , Perry E. , MacDougall L. , et al. (2004) The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis . Neuropsychopharmacology 29: 1558-1572.

Grotenhermen F. ( 2003) Pharmacokinetics and pharmacodynamics of cannabinoids . Clin Pharmacokinet 42: 327-360.

Hall W. , Solowij N. ( 1998) Adverse effects of cannabis. Lancet 352: 1611-1616.

Lever IJ , Rice AS ( 2007) Cannabinoids and pain. Handbook of Experimental Pharmacology 177: 265-306.

10.

Russo E. ( 2006) A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66: 234-246.

11.

Sidney S. ( 2002) Cardiovascular consequences of marijuana use. J Clin Pharmacol 42: 64S-70S.

12.

Schmitt JAJ ( 2001) Serotonin, caffeine and cognition: psychopharmacological studies in human cognitive functioning. Thesis. Maastricht : NeuroPsych Publishers.

13.

Tramer MR , Carroll D. , Campbell FA , Reynolds DJ , Moore RA , McQuay HJ ( 2001) Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. Brit Med J 323: 16-21.

14.

Wright BM ( 1971) A simple mechanical ataxia-meter. J Physiol 218: 27P-28P.

15.

Zuurman L. , Passier Pccm , de Kam ML , Kleijn HJ , Cohen AF , van Gerven JMA ( 2009) Pharmacodynamic and pharmacokinetic effects of the intravenously administered CB1 receptor agonist Org 28611 in healthy male volunteers. J Psychopharmacol 23(6): 633-644.

16.

Zuurman L. , Roy C. , Schoemaker RC , et al. (2008a) Effect of intrapulmonary THC administration in humans. J Psychopharmacol 22: 707-716.

17.

Zuurman L. , Roy C. , Schoemaker RC , et al. (2008b) Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625 . J Psychopharmacol (accessed 21 November 2008).

18.

Zuurman L. , van Gerven JMA , Asgarali F. , Burggraaf J. ( 2006) Effect of acute THC administration on heart rate variability in humans. Brit J Clin Pharmacol 61: 485-486.